Bonn Team Converts Elderly Blood Cells Into Neural Stem Cells 60 Years Younger on Epigenetic Clock

Researchers at the University Hospital of Bonn and the University of Bonn have demonstrated something that sounds like it belongs in a longevity marketing deck but is, in fact, a peer-reviewed laboratory result: blood-cell precursors taken from an 80-year-old donor can be reprogrammed into neural stem cells carrying a molecular age signature of less than 20 years.

The work, published in Aging Cell on October 3, 2026, does not describe a treatment. It describes a cellular biology experiment, and the distinction matters.

The team, led by Prof. Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at University Hospital Bonn, used specialized transcription factors to convert erythroid precursors, immature red blood cells, directly into induced neural stem cells. The key departure from standard cellular reprogramming is that the Bonn protocol skips the fully pluripotent stage that conventional iPSC methods pass through. That detour turns out to matter enormously for observation.

In most reprogramming workflows, epigenetic age reversal happens fast, compressed into an early phase that's hard to dissect. Here, because the cells converted without passing through pluripotency, the epigenetic clocks reset gradually. As reported in Aging Cell, the researchers were able to track the rejuvenation process for more than 100 days, giving them an unusually long experimental window into the mechanics of de-aging.

When the team applied established epigenetic clocks to the finished cells, the numbers were striking. Cells from an 80-year-old donor emerged from the conversion carrying a molecular age of less than 20 years, a rollback of roughly six decades. The converted cells also functionally behaved like young neural stem cells, not just displaying younger chemical signatures but adopting the characteristics expected of youthful cells.

That functional alignment is the part worth watching. Epigenetic age estimates are proxies, not definitive readouts of cellular health, and a cell can score young on a methylation clock while still being dysfunctional in ways the clock doesn't capture. The Bonn team acknowledged that the study examined cells under controlled in vitro conditions, and that those conditions don't map directly onto what happens inside a living organism.

The sample here is also worth naming plainly. This is laboratory work on cells from individual donors, not a clinical trial and not a rodent cohort. The leap from dish to body is not a small one, and nothing in this paper shortens it.

What the paper does offer is a model. Because rejuvenation unfolds slowly in the Bonn protocol, researchers can now ask which molecular factors accelerate or retard the process, and potentially test interventions against a legible timeline. That's a genuine methodological contribution to the broader cellular reprogramming field, even if the headline number, 60 years of age reversal, will predictably outrun the nuance in public coverage.

The research involved collaborators from RWTH Aachen University and received funding from the European Union's Horizon 2020 program, the German Research Foundation, and the German Federal Ministry of Research, Technology, and Space. The paper is titled "Protracted Fate Acquisition and Epigenetic De-Aging During Induced Neural Stem Cell Conversion of Human Blood Cells" and is available via DOI 10.1111/acel.70751.

Sources cited:
- Aging Cell (Berg et al., 2026) (https://onlinelibrary.wiley.com/doi/10.1111/acel.70751)
- University of Bonn press release (https://www.uni-bonn.de/en/news/211-2026)
- ScienceDaily, University of Bonn (https://www.sciencedaily.com/releases/2026/10/261020085013.htm)
- Bioengineer.org (https://bioengineer.org/blood-cells-from-80-year-olds-rejuvenated-into-brain-cells-with-molecular-age-under-20/)
- News-Medical.net (https://www.news-medical.net/news/20261009/Bonn-researchers-successfully-rejuvenate-human-cells-in-a-test-tube.aspx)